<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37193133</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-8927</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cell insight</Title><ISOAbbreviation>Cell Insight</ISOAbbreviation></Journal><ArticleTitle>Identification of a novel binding inhibitor that blocks the interaction between hSCARB2 and VP1 of enterovirus 71.</ArticleTitle><Pagination><StartPage>100016</StartPage><MedlinePgn>100016</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100016</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cellin.2022.100016</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV-A71) infection causes severe hand-foot-and-mouth disease that leads to cardiopulmonary complications and death in young children under 5 years of age. Although there are available vaccines for EV-A71 C<sup>4</sup>, however, there are no efficient drugs for severe cases. Thus, there is an urgent need to find new direct-antiviral agents (DAAs) to control EV-A71 infection. In this study, we report our discovery of the EV-A71 capsid inhibitor PTC-209HBr, a small-molecule Bmi-1 inhibitor and an anticancer agent, and its derivatives that inhibit multiple enteroviruses with an EC<sub>50</sub> at a submicromolar efficacy. The mechanism of action of PTC-209HBr was confirmed by time-of-addition, resistance selection and reverse genetics experiments, microscale thermophoresis (MST), viral binding and entry assays, coimmunoprecipitation (Co-IP) and immunofluorescence experiments (IF). Mechanistic studies indicated that PTC-209HBr inhibited EV-A71 infection by impeding the binding between VP1 and the receptor hSCARB2 during the early stage of EV-A71 infection through hindering viral entry into host cells. Collectively, these findings indicated that PCT-209HBr is a novel inhibitor of enteroviruses with a confirmed mechanism of action that can be further developed into EV-A71 DAAs.</AbstractText><CopyrightInformation>&#xa9; 2022 Wuhan University.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Microbiology, The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Zhichao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yinuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Baojing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Microbiology, The Key Laboratory of Microbiology and Parasitology of Anhui Province, The Key Laboratory of Zoonoses of High Institutions in Anhui, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Hai-Bing</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Hubei Provincial Key Laboratory of Developmentally Originated Disease, Hubei Province Engineering and Technology Research Center for Fluorinated Pharmaceuticals, Wuhan University School of Pharmaceutical Sciences, Wuhan, 430071, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Research Institute, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, 430071, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Cell Insight</MedlineTA><NlmUniqueID>9918557775706676</NlmUniqueID><ISSNLinking>2772-8927</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DAAs</Keyword><Keyword MajorTopicYN="N">EV-A71</Keyword><Keyword MajorTopicYN="N">Enterovirus</Keyword><Keyword MajorTopicYN="N">Enviroxime</Keyword><Keyword MajorTopicYN="N">PTC-209HBr</Keyword><Keyword MajorTopicYN="N">Pirodavir</Keyword><Keyword MajorTopicYN="N">VP1</Keyword><Keyword MajorTopicYN="N">hSCARB2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>12</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>21</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37193133</ArticleId><ArticleId IdType="pmc">PMC10120312</ArticleId><ArticleId IdType="doi">10.1016/j.cellin.2022.100016</ArticleId><ArticleId IdType="pii">S2772-8927(22)00013-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals blocking entry of enteroviruses and therapeutic potential. J.&#xa0;Biomed. Sci. 2021;28:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Baer A., Kehn-Hall K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. JoVE. 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4255882</ArticleId><ArticleId IdType="pubmed">25407402</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L.Y., Lin T.Y., Hsu K.H., Huang Y.C., Lin K.L., Hsueh C., Shih S.R., Ning H.C., Hwang M.S., Wang H.S., et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease. Lancet. 1999;354:1682&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pubmed">10568570</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M., Wang X., Wang Q., Wang Y., Lin J., Sun Y., Li X., Zhang L., Lou Z., Wang J., et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5:692&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Entzian C., Schubert T. Studying small molecule&#x2013;aptamer interactions using MicroScale Thermophoresis (MST) Methods. 2016;97:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">26334574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleischer R., Laessig K. Safety and efficacy evaluation of pleconaril for treatment of the common cold. Clin. Infect. Dis. 2003;37:1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunaseelan S., Wong K.Z., Min N., Sun J., Ismail N., Tan Y.J., Lee R.C.H., Chu J.J.H. Prunin suppresses viral IRES activity and is a potential candidate for treating enterovirus A71 infection. Sci. Transl. Med. 2019;11</Citation><ArticleIdList><ArticleId IdType="pubmed">31666401</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Sun N., Wu H., Guo D., Tien P., Dong C., Wu S., Zhou H.B. Identification and structure-activity relationships of diarylhydrazides as novel potent and selective human enterovirus inhibitors. J.&#xa0;Med. Chem. 2016;59:2139&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">26885567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopcraft S.E., Pattenden S.G., James L.I., Frye S., Dittmer D.P., Damania B. Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 2018;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6136816</ArticleId><ArticleId IdType="pubmed">30212584</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh C.F., Jheng J.R., Lin G.H., Chen Y.L., Ho J.Y., Liu C.J., Hsu K.Y., Chen Y.S., Chan Y.F., Yu H.M., et al. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors. Emerg. Microb. Infect. 2020;9:1194&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448925</ArticleId><ArticleId IdType="pubmed">32397909</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Musharrafieh R., Zheng M., Wang J. Enterovirus D68 antivirals: past, present, and future. ACS Infect. Dis. 2020;6:1572&#x2013;1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.W., Hsu Y.W., Smith D.J., Kiang D., Tsai H.P., Lin K.H., Wang S.M., Liu C.C., Su I.J., Wang J.R. Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J.&#xa0;Clin. Microbiol. 2009;47:3653&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772620</ArticleId><ArticleId IdType="pubmed">19776232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen S.B., Fahn&#xf8;e U., Pham L.V., Serre S.B.N., Tang Q., Ghanem L., Pedersen M.S., Ramirez S., Humes D., Pihl A.F., et al. Evolutionary pathways to persistence of highly fit and resistant Hepatitis C virus protease inhibitor escape variants. Hepatology. 2019;70:771&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772116</ArticleId><ArticleId IdType="pubmed">30964552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Kim C., Kim D.E., Song J.H., Choi M., Choi K., Kang M., Lee K., Kim H.S., Shin J.S., et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antivir. Res. 2015;124:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.M., Chen C.J., Shih S.R. Regulation mechanisms of viral IRES-driven translation. Trends Microbiol. 2017;25:546&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">28242053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.-Y., Kung Y.-A., Shih S.-R. Antivirals and vaccines for enterovirus A71. J.&#xa0;Biomed. Sci. 2019;26:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6720414</ArticleId><ArticleId IdType="pubmed">31481071</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsuwanon P., Puenpa J., Huang S.W., Wang Y.F., Mauleekoonphairoj J., Wang J.R., Poovorawan Y. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J.&#xa0;Biomed. Sci. 2014;21:16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3937078</ArticleId><ArticleId IdType="pubmed">24548776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou Z., Sun Y., Rao Z. Current progress in antiviral strategies. Trends Pharmacol. Sci. 2014;35:86&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112804</ArticleId><ArticleId IdType="pubmed">24439476</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterback R., Vuorinen T., Linna M., Susi P., Hyypi&#xe4; T., Waris M. Coxsackievirus A6 and hand, foot, and mouth disease, Finland. Emerg. Infect. Dis. 2009;15:1485&#x2013;1488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819858</ArticleId><ArticleId IdType="pubmed">19788821</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham L.V., Jensen S.B., Fahn&#xf8;e U., Pedersen M.S., Tang Q., Ghanem L., Ramirez S., Humes D., Serre S.B.N., Sch&#xf8;nning K., et al. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape. J.&#xa0;Hepatol. 2019;70:388&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">30395912</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R.J., Rossmann M.G. Crystal structure of human enterovirus 71. Science. 2012;336:1274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann M.G., He Y., Kuhn R.J. Picornavirus-receptor interactions. Trends Microbiol. 2002;10:324&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">12110211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjuan R., Domingo-Calap P. Mechanisms of viral mutation. Cell. Mol. Life Sci. 2016;73:4433&#x2013;4448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075021</ArticleId><ArticleId IdType="pubmed">27392606</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang B., Deng C., Ye H., Xu W., Yuan Z., Shi P.Y., Zhang B. Development and characterization of a stable eGFP enterovirus 71 for antiviral screening. Antivir. Res. 2013;97:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">23267829</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia K.S., Li W.T., Chang C.M., Hsu M.C., Chern J.H., Leong M.K., Tseng S.N., Lee C.C., Lee Y.C., Chen S.J., et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J.&#xa0;Med. Chem. 2002;45:1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 2010;10:778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Lee H., Thibaut H.J., Lanko K., Rivero-Buceta E., Bator C., Martinez-Gualda B., Dallmeier K., Delang L., Leyssen P., et al. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 2019;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590834</ArticleId><ArticleId IdType="pubmed">31071193</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Li S., Du L., Chen S., Gao J., Cai Y., Xu Z., Zhao Z., Lan K., Wu S. Emetine protects mice from enterovirus infection by inhibiting viral translation. Antivir. Res. 2020;173:104650.</Citation><ArticleIdList><ArticleId IdType="pubmed">31734270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Wu Y.Q., Chen D.S., Zhou Q., Chen H.C., Liu Z.F. Bovine herpesvirus 5 encodes a unique pattern of microRNAs compared with bovine herpesvirus 1. J.&#xa0;Gen. Virol. 2014;95:671&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">24385436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Xu Z., Jin M., Shu T., Chen Y., Feng L., Zhang Q., Lan K., Wu S., Zhou H.B. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur. J. Med. Chem. 2020;202:112310.</Citation><ArticleIdList><ArticleId IdType="pubmed">32619885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tijsma A., Franco D., Tucker S., Hilgenfeld R., Froeyen M., Leyssen P., Neyts J. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 2014;58:6990&#x2013;6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4249361</ArticleId><ArticleId IdType="pubmed">25199773</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosteson M.T., Chow M. Characterization of the ion channels formed by poliovirus in planar lipid membranes. J.&#xa0;Virol. 1997;71:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191079</ArticleId><ArticleId IdType="pubmed">8985378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm. Sin. B. 2021 doi: 10.1016/j.apsb.2021.08.017. In press.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Li X., Yin M., Wang H., Qin L., Li H., Liu W., Zhao Z., Zhao Q., Chen H., et al. Selective autophagy receptor SQSTM1/p62 inhibits Seneca Valley virus replication by targeting viral VP1 and VP3. Autophagy. 2021:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8632295</ArticleId><ArticleId IdType="pubmed">33719859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Yeo A., Phoon M.C., Tan E.L., Poh C.L., Quak S.H., Chow V.T. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int. J. Infect. Dis. 2010;14:e1076&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pubmed">20952237</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia H., Wang P., Wang G.C., Yang J., Sun X., Wu W., Qiu Y., Shu T., Zhao X., Yin L., et al. Human enterovirus nonstructural protein 2CATPase functions as both an RNA helicase and ATP-independent RNA chaperone. PLoS Pathog. 2015;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517893</ArticleId><ArticleId IdType="pubmed">26218680</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 2014;14:308&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Ma S., Zhu L., Huang Z., Chen L., Xu Y., Yin H., Peng T., Wang Y. Clinically isolated enterovirus A71 subgenogroup C4 strain with lethal pathogenicity in 14-day-old mice and the application as an EV-A71 mouse infection model. Antivir. Res. 2017;137:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">27864074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Liu F., Liao Q., Wu P., Chang Z., Huang J., Long L., Luo L., Li Y., Leung G.M., et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y., Tang Q., Xu Z., Li S., Jin M., Zhao Z., Dong C., Wu S., Zhou H.B. Synthesis and structure-activity relationship study of arylsulfonamides as novel potent H5N1 inhibitors. Eur. J. Med. Chem. 2018;159:206&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">30292897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng M., El Khatib N.F., Tu S., Ren P., Xu S., Zhu Q., Mo X., Pu D., Wang X., Altmeyer R. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J.&#xa0;Clin. Virol. 2012;53:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265829</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D., Zhao Y., Kotecha A., Fry E.E., Kelly J.T., Wang X., Rao Z., Rowlands D.J., Ren J., Stuart D.I. Unexpected mode of engagement between enterovirus 71 and its receptor SCARB2. Nat. Microbiol. 2019;4:414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">30531980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>